Abstract

Anti-Müllerian hormone (AMH) is a member of the TGF-β superfamily secreted by the gonads of both sexes. This hormone is primarily known for its role in the regression of the Müllerian ducts in male fetuses. In females, AMH is expressed in granulosa cells of developing follicles. Like other members of the TGF-β superfamily, AMH transduces its signal through two transmembrane serine/threonine kinase receptors including a well characterized type II receptor, AMHR-II. The complete signalling pathway of AMH involving Smads proteins and the type I receptor is well known in the Müllerian duct and in Sertoli and Leydig cells but not in granulosa cells. In addition, few AMH target genes have been identified in these cells. Finally, while several co-receptors have been reported for members of the TGF-β superfamily, none have been described for AMH. Here, we have shown that none of the Bone Morphogenetic Proteins (BMPs) co-receptors, Repulsive guidance molecules (RGMs), were essential for AMH signalling. We also demonstrated that the main Smad proteins used by AMH in granulosa cells were Smad 1 and Smad 5. Like for the other AMH target cells, the most important type I receptor for AMH in these cells was BMPR-IA. Finally, we have identified a new AMH target gene, Id3, which could be involved in the effects of AMH on the differentiation of granulosa cells and its other target cells.

Highlights

  • Anti-Mullerian hormone (AMH) called Mullerian inhibiting substance (MIS) is a member of the TGF-b superfamily

  • Primary cultures of immature mouse granulosa cells To identify the different components of the AMH signalling pathway in GCs, we first isolated immature GCs from 3 weeks old mice [33] and we characterized them for different criteria

  • We report that AMH up-regulates Id3, through BMPR-IA and that only Smad 1/5 are activated by AMH in these cells

Read more

Summary

Introduction

Anti-Mullerian hormone (AMH) called Mullerian inhibiting substance (MIS) is a member of the TGF-b superfamily. AMH is well known for its role in Mullerian duct regression in male fetuses [1]. AMH is a negative regulator of the primordial to primary follicle transition [2]. In addition it decreases FSH sensitivity of growing follicles [3]. Serum AMH is widely used in oncology and gynecology. It is a very useful diagnostic and prognostic tool, as an early indicator of relapse of ovarian GC tumors [4] and as a reliable marker of the ovarian follicular status. Despite the increasing interest of ovarian AMH in clinics, little is known on its mechanism of action on GCs

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call